MCM
BMY.RT

Maple Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Maple Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,624
Closed -$7K – 104
2020
Q4 		$7K Sell
10,624
-600
-5% -$1.28K ﹤0.01% 100
2020
Q3 		$14K Buy
11,224
+600
+6% +$1.71K ﹤0.01% 103
2020
Q2 		$38K Hold
10,624
– – 0.01% 97
2020
Q1 		$40K Hold
10,624
– – 0.01% 90
2019
Q4 		$32K Buy
+10,624
New +$27.6K 0.01% 122

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Maple Capital Management's BMY.RT Position: Q1 2021 in Review

Maple Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 10,624 shares — an estimated $7K sold.

Maple Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $40K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Maple Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Maple Capital Management sold 10,624 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $7K.
  • Maple Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Maple Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $40K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Maple Capital Management's 13F filing for Q1 2021, filed 14 May 2021.